Marlborough, Massachusetts–based Boston Scientific announced an agreement to acquire the urinary incontinence treatment developer in January. The companies did not disclose the financial details of the acquisition.
This marks the latest major acquisition for the company’s Urology portfolio, which added Axonics in 2024.
Valencia Technologies develops solutions for treating bladder dysfunction. Its FDA-approved eCoin implantable tibial nerve stimulation (ITNS) device treats urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB). It competes against Medtronic’s Altaviva minimally invasive ITNM device, which won FDA approval last year.
eCoin, a coin-sized device, is placed under the skin, near the ankle, in a minimally invasive procedure. Valencia designed the device for patients who have undergone a successful trial of percutaneous tibial nerve stimulation (PTNS) or for patients who are intolerant to or have an inadequate response to more conservative UUI treatments.
Once implanted, the device intermittently and automatically stimulates the tibial nerve to help regulate how the brain communicates with the bladder. A clinical trial demonstrated 68% patient responding with at least a 50% reduction in UUI episodes.
“The acquisition of Valencia Technologies expands Boston Scientific’s pelvic health portfolio to include ITNS, a rapidly growing segment where the company does not currently have an offering,” a Boston Scientific spokesperson said via email. “This strategic expansion broadens the treatment options Boston Scientific offers to physicians for patients suffering from pelvic health disorders.”
This marks the second acquisition completed by Boston Scientific in 2026, following the closing of its deal to acquire Nalu Medical. The company also agreed to a $14.5 billion deal to buy Penumbra in January, just days after announcing the Valencia deal.
